Ximelagatran: An oral direct thrombin inhibitor

Annals of Pharmacotherapy

Volumn 38, Issue 11, 2004, Pages 1881-1897

  Dager, William E ^a,b,c   Vondracek, Thomas G ^d   McIntosh, Bruce A ^e,f   Nutescu, Edith A ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Exempla Saint Joseph Hospital   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f LEXINGTON VA MEDICAL CENTER   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Deep vein thrombosis; Direct thrombin inhibitors; Melagatran; Thromboembolism; Ximelagatran

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DALTEPARIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HEPARIN; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NITRIC ACID DERIVATIVE; PRODRUG; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LIVER DYSFUNCTION; MEDLINE; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; AZETIDINES; BENZYLAMINES; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; VENOUS THROMBOSIS;

EID: 7244232920     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E078     Document Type: Review

References (99)

1. Kaplan KL. Direct thrombin inhibitors. Expert Opin Pharmacother 2003;4:653-66.
2. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmstrom M, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-63.
3. Gustafsson D, Nystrom JE, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
4. Eriksson UG, Bredberg U, Huffman KJ, Thuresson A, Gabrielsson M, Ericsson H, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
5. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43.
6. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645-51.
7. Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997;77:498-503.
8. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38:99-109. DOI 10.1345/aph.1D066
9. Bredberg U, Eriksson U, Taure K, Johansson L, Frison L, Gustafsson D. Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration (abstract). Blood 1999;94:28a.
10. Wolzt M, Wollbratt M, Svensson M, Wahlander K, Grind M, Eriksson UG. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003;59:537-43.
11. Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wahlby U, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet 2003;42:687-701.
12. Eriksson UG, Frisson L, Gustafsson D, Mandema J, Karlsson MO, Eriksson B. Pharmacokinetics of melagatran, the active form of the direct thrombin inhibitor H 375/95, in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism (abstract). Blood 2000;96:93b.
13. Harenberg J, Fenyvesi T, Jorg I. Inhibition of blood coagulation by ximelagatran in patients with a first episode of symptomatic acute deep vein thrombosis for prophylaxis of recurrent events (abstract). Thromb Haemost 2003;(1 suppl 1):P1905.
14. Sarich TC, Teng R, Peters GR, Wollbratt M, Homolka R, Svensson M, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003;42:485-92.
15. Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003;42:743-53.
16. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-92.
17. Johansson LC, Andersson M, Fager G, Gustafsson D, Erikkson UG. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003:42:475-84.
18. Hellegren M, Johansson S, Eriksson UG, Wahlander K. Excretion of the oral direct thrombin inhibitor ximelagatran into breast milk following oral administration to breast-feeding women (abstract). J Thromb Haemost 2003;(1 suppl 1):P1992.
19. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:755-64.
20. Schutzer K-M, Wall U, Lonnerstedt CE, Ohlsson LM, Teng R, Sarich TC, et al. Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. Curr Med Res Opin 2004;20:325-31.
21. Sarich TC, Johansson S, Schutzer KM, Wall U, Kessler E, Teng R, et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004;44:388-93.
22. Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003;59:283-9.
23. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-77.
24. Teng R, Sarich TC, Eriksson UG, Hamer JE, Gillette S, Schutzer KM, et al. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 2004;44:1063-71. DOI 10.1177/0091270004268446
25. Sarich TC, Schutzer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004;44:935-41. DOI 10.1177/0091270004268048
26. Hankey GJ, Klijn CS, Eikelboom JW. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation? Stroke 2004;35:389-91.
27. Sarich TC, Schutzer KM, Dorani H, Wall U, Kalies I, Ohlsson L, et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004;44:928-34. DOI 10.1177/0091270004268047
28. Dorani H, Schutzer K, Sarich T, Wall U, Ohlsson L, Eriksson UG. The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with erythromycin. Presented at: 18th International Congress on Thrombosis, 2004. www.thrombosis2004.org/main.htm (accessed 2004 Sep 2).
29. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
30. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
31. Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double blind, prospective, randomized, placebo-controlled study with dalteparin (fragmin). Thromb Haemost 1997;77:26-31.
32. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
33. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A:336-45.
34. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2208-15.
35. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl): 132S-75S.
36. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
37. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003;89:288-96.
38. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blinded trial. Ann Intern Med 2002;137:648-55.
39. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
40. Owen OG. The EXPRESS study: preliminary results. Int J Clin Pract 2003;57:57-9.
41. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6.
42. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003;1:2119-30.
43. Colwell CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B (abstract). Blood 2003;102:14a.
44. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(suppl):176S-93S.
45. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-7.
46. Huisman MV, on behalf of the THRIVE Treatment Study Investigators, Netherlands. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study (abstract OC003). J Thromb Haemost 2003;(1 suppl 1).
47. Francis CW, Ginsberg JS, Berkowitz SD, Bounameaux H, Davidson BL, Eriksson H, et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study (abstract). Blood 2003;102:6a.
48. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
49. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;199(suppl):64S-94S.
50. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for the treatment of acute venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
51. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9.
52. Schulman S, Granqvsit S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
53. Ridker PM, Goldhaber SZ, Danielsori E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term, low-intensity, warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1-10.
54. Albers GW, Dalen JE, Laupacis A, Manning WJ, Peterson P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(suppl): 194S-206S.
55. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW; on behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Stroke 1999;30:1223-9.
56. Hyleck EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
57. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95.
58. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
59. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
60. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
61. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000;160:967-73.
62. Petersen P, Grind M, Adler J, SPORTIF II investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003;41:1445-51.
63. Petersen P, on behalf of the SPORTIF II and IV investigators. A long-term follow-up of ximelagatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (abstract). Blood 2001;98:706a.
64. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III); randomized controlled trial. Lancet 2003;362:1691-8.
65. Halperin JL, Executive steering committee, SPORTIF III and V study investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8.
66. The Executive Steering Committee on behalf of the SPORTIF V investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Circulation 2003;108:2723(J).
67. Halperin JL. Efficacy and safety study of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V) American Heart Association Scientific sessions. Proc Am Heart Assoc, Orlando, FL, November 9-12, 2003.
68. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557-63.
69. The OASIS Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001;37:475-84.
70. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
71. van Es RF, Jonker JJ, Verbeugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) research group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
72. Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-65.
73. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
74. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodwin A, Nystrom P, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
75. Dager WE, Gosselin RC, Owings JT. Argatroban in antithrombin deficiency and mesenteric thrombosis: a case report and review of the literature. Pharmacotherapy 2004;24:659-63.
76. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001;135(8 pt 1):589-93.
77. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003;4:919-40.
78. Seth SB, Dicicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-40.
79. Gosselin RC, Dager WE, King JH, Janatpour KA, Mahackian K, Larkin EC, et al. Effect of direct-thrombin-inhibitor (DTI) anticoagulants on INR measurements and other coagulation studies (abstract). Blood 2003;102:810a-1a.
80. Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin EC, et al. Effect of direct-thrombin-inhibitors: bivalirudin, lepirudin, and argatroban, on prothrombin time and INR measurements. Am J Clin Pathol 2004;121:593-9.
81. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999;78:285-91.
82. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I, MElagatran for THrombin inhibition in orthopaedic surgery. Thromb Haemost 2002;87:231-7.
83. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001;161:2215-21.
84. Dager WE, White RH. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 2003;37:1232-6. DOI 10.1345/aph.1D010
85. Wolzt M, Levi M, Sarich TC, Bostrom SL, Eriksson UG, Eriksson-Lepkowska M, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004;91:1090-6.
86. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-57.
87. Ulvinge J, Berntsson P, Bostrom L. Melagatran-induced inhibition of thrombin generation is reversed by FIBA™ (abstract). Blood 2000;96:103b.
88. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004;38:1383-8. DOI 10.1345/aph.1D565
89. Mattsson C, Lundin-Menscik A, Wahlander K, Lindahl TL. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilation of the plasma sample. Thromb Haemost 2001;86:611-5.
90. de Denus S, Spinler SA. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy 2002;22:433-5.
91. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-8.
92. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
93. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis SN, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16.
94. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71.
95. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003;145:438-44.
96. Olsson SB, for the SPORTIF Executive Steering Committee. Author reply. Lancet 2004;363:736-7.
97. Ericksson UG, Samuelsson O, Attman PO, Lepowska M, Ohlsson L, Carlsson S, et al. Melagatran is efficiently eliminated by hemodialysis in uremic patients. Presented at: 18th International Congress on Thrombosis, 2004. www.thrombosis2004.org/main.htm (accessed 2004 Sep 2).
98. Package insert. Exanta (ximelagatran), Lund, Sweden: AstraZeneca, 2004.
99. Dager WE. Initiating warfarin therapy. Ann Pharmacother 2003;37:905-8. DOI 10.1345/aph.ID038